Cell Source, Inc.

Equities

CLCS

US15114L1044

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 02:57:38 2024-04-19 pm EDT			5-day change	1st Jan Change
0.0002 ^USD	-99.95%		0.00%	-99.96%

Mar. 22	Cell Source, Inc. announced that it has received $4.76017 million in funding	CI
2023	Cell Source, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

CELL SOURCE, INC. : Change in Directors or Principal Officers (form 8-K)

May 06, 2022 at 05:09 pm EDT

ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTOR; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS

On May 6, 2022 Itamar Shimrat resigned his position as a director of Cell Source, Inc. (the "Company"). Mr. Shimrat's resignation was not the result of any disagreement with the Company and he will continue in his positions as President and Chief Executive Officer. Mr. Shimrat's resignation as director follows an evaluation of the structure of the Board of Directors and a determination that it is in the best interest of the Company to have a Board of Directors comprised of an odd number of members to reduce the possibility of a deadlock.

Latest news about Cell Source, Inc.

Cell Source, Inc. announced that it has received $4.76017 million in funding	Mar. 21	CI
Cell Source, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Cell Source, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-09-19	CI
Cell Source, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-08-23	CI
Cell Source, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-08-08	CI
Cell Source, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-12-08	CI
Cell Source, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-12-02	CI
Cell Source, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-11-02	CI
Cell Source, Inc. Announces Board Resignations	22-07-21	CI
Cell Source, Inc. Announces Resigation of Itamar Shimrat as A Director	22-05-06	CI
Cell Source, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-15	CI
Cell Source, Inc. Auditor Raises 'Going Concern' Doubt	22-04-14	CI
Cell Source, Inc. Appoints George Verstraete as Member	22-03-11	CI
Cell Source, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-15	CI
Cell Source, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-12	CI
Cell Source, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-17	CI
Cell Source, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-15	CI
Cell Source, Inc. Appoints Darlene Soave to its Board of Directors, Effective May 25, 2021	21-04-01	CI
USPTO Issues New Patents for Cell Source's Veto Cell Technology	21-03-19	CI
Cell Source, Inc. Announces its Veto T-Cell Bone Marrow Transplant Safely Demonstrates Potential Cure for Sickle Cell Anemia in Preclinical Trials	21-03-12	CI
Cell Source, Inc. Appoints Joseph Rosenthal to Scientific Advisory Board	21-02-25	CI
Cell Source, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-13	CI
Cell Source, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-14	CI
Cell Source, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-15	CI
Cell Source, Inc. Announces Resignation of Yoram Drucker as Director	19-04-19	CI

Chart Cell Source, Inc.

Duration

Period

More charts

Company Profile

Cell Source, Inc. is a cell therapy company focused on immunotherapy. The Company is primarily focused on the development of immune system management technology (Veto Cell technology). Its lead prospective product is its Veto Cell immune system management technology. Its Veto Cell technology is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is in pre-clinical phase, and its data shows that it provides results in allogeneic (donor-derived) hematopoietic stem cell transplantation (HSCT) by allowing for haploidentical stem cell transplants under a mild conditioning regimen. Its product pipeline includes chimeric antigen receptor (CAR) T-cell therapies, which include VETO CAR-T (with or without HSCT) for B-cell malignancies, Veto Cell kidney transplants, VETO CAR-T for solid tumors, Veto Cell liver transplants, and Veto HSCT for non-malignant disorders. The Company's wholly owned subsidiary is Cell Source Limited (CSL).

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CELL SOURCE, INC.	-99.96%	8.2K
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs